⌕
Definium Therapeutics · DFTX · Nasdaq
Tenet 50 · Mixed
Compare
$29.38−2.59%At closeTenet 50 · Mixed
$29.38−0.78 (−2.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Definium Therapeutics (DFTX) Institutional Ownership

13F filers reported holding 45.7% of Definium Therapeutics (DFTX) shares as of Sep 30, 2026, across 257 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
45.7%
Sep 30, 2026
13F filers
257
quarter ended Sep 30, 2026
13F value
$2.4B
62.5M shares
Quarter's fund flow
Mild accumulation
46 new · 44 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (46 new · 102 increased · 62 reduced · 44 closed · 3 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 257 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 25, 2026Karlin DanChief Medical OfficerDisposed · Open-market sale10,853Common Shares$36.57↗
Sep 25, 2026Barrow RobertChief Executive OfficerDisposed · Open-market sale31,550Common Shares$36.57↗
Sep 25, 2026Wiley Matthew T.Chief Commercial OfficerDisposed · Open-market sale3,097Common Shares$36.57↗
Sep 25, 2026Sullivan MarkChief Legal OfficerDisposed · Open-market sale14,051Common Shares$36.57↗
Sep 25, 2026Roberts BrandiChief Financial OfficerDisposed · Open-market sale3,377Common Shares$36.57↗
Sep 18, 2026Krebs AndreasdirectorAcquired · Option exercise1,629Common Shares$35.52↗
Sep 18, 2026Krebs AndreasdirectorDisposed · Option exercise1,629Stock Option (Right to Buy)—↗
Sep 18, 2026Vallone Carol AdirectorAcquired · Option exercise1,086Common Shares$35.52↗
Sep 18, 2026Vallone Carol AdirectorDisposed · Option exercise1,086Stock Option (Right to Buy)—↗
Sep 14, 2026Karlin DanChief Medical OfficerAcquired · Grant / award200,000Common Shares—↗
Sep 14, 2026Wiley Matthew T.Chief Commercial OfficerAcquired · Grant / award125,000Common Shares—↗
Sep 14, 2026Sullivan MarkChief Legal OfficerAcquired · Grant / award125,000Common Shares—↗
Sep 14, 2026Roberts BrandiChief Financial OfficerAcquired · Grant / award125,000Common Shares—↗
Sep 14, 2026Barrow RobertChief Executive OfficerAcquired · Grant / award750,000Common Shares—↗
Sep 3, 2026Barrow RobertChief Executive OfficerDisposed · Open-market sale19,023Common Shares$37.94↗
Sep 2, 2026Barrow RobertChief Executive OfficerAcquired · Grant / award40,000Common Shares—↗
Aug 12, 2026Barrow RobertChief Executive OfficerAcquired · Grant / award375,000Common Shares—↗
Aug 12, 2026Karlin DanChief Medical OfficerAcquired · Grant / award100,000Common Shares—↗
Aug 12, 2026Sullivan MarkChief Legal OfficerAcquired · Grant / award62,500Common Shares—↗
Aug 12, 2026Wiley Matthew T.Chief Commercial OfficerAcquired · Grant / award62,500Common Shares—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Definium Therapeutics do institutions hold?

13F filers reported holding 45.7% of Definium Therapeutics' shares as of Sep 30, 2026, across 257 filers.

How many 13F filers hold Definium Therapeutics?

Definium Therapeutics was held by 257 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.